Investor SentimentCronos Group's enterprise value is slightly negative, attributed to the lack of US reform and investor restrictions, which pressures the stock compared to its peers.
Regulatory ChallengesRegulatory challenges, including unclear US federal cannabis reform and changes to the Canadian Cannabis Act, are significant factors that negatively impact the stock's valuation.
Stock ValuationThe company's valuation is expected to remain low due to slow progress on US federal cannabis reform, despite improvements in sales and cost management.